Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study.

abstract：:The aim of this study was to define factor(s) influencing fetal erythropoiesis following bone marrow transplantation. Thirty-one transplanted patients (14 males, 17 females) were studied. The underlying diseases were chronic myelogenous leukaemia (CML, 18 patients), acute myeloblastic leukaemia (AML, 7 patients) and a...

journal_title：Bone marrow transplantation

authors： Meletis J,Papavasiliou S,Yataganas X,Vavourakis S,Konstantopoulos K,Poziopoulos C,Samarkos M,Michali E,Dalekou M,Eliopoulos G

更新日期：1994-11-01 00:00:00

abstract：:Hematopoietic SCT (HSCT) and high-dose chemotherapy are being explored as therapy for various human refractory immune-mediated conditions, including inflammatory bowel diseases (IBD). Nevertheless, the exact immunological mechanisms by which the BM cells (BMCs) or immunosuppression provide remission from these disease...

journal_title：Bone marrow transplantation

authors： Godoi DF,Cardoso CR,Ferraz DB,Provinciatto PR,Cunha FQ,Silva JS,Voltarelli JC

更新日期：2010-10-01 00:00:00

abstract：:In allo-stem cell transplantation (SCT), it is unclear whether donor-specific anti-HLA Abs (DSAs) can actually mediate graft rejection or if they are simply surrogate markers for the cellular immunity that causes graft rejection. Here, we first analyzed a case of cord blood allograft rejection in which DSA and cytotox...

journal_title：Bone marrow transplantation

authors： Hanajiri R,Murata M,Sugimoto K,Murase M,Sakemura R,Goto T,Watanabe K,Imahashi N,Terakura S,Ohashi H,Akatsuka Y,Kurahashi S,Miyamura K,Kiyoi H,Nishida T,Naoe T

更新日期：2015-09-01 00:00:00

abstract：:The study was designed to determine whether the number of CD34+/CD33- cells given at autologous peripheral blood stem cell (PBSC) rescue after intensive therapy for cancer was a better predictor of platelet engraftment than the total number of CD34+ cells infused. Comparison between the total number of CD34+ cells/kg ...

journal_title：Bone marrow transplantation

authors： Millar BC,Millar JL,Shepherd V,Blackwell P,Porter H,Cunningham D,Judson I,Treleaven J,Powles RL,Catovsky D

更新日期：1998-09-01 00:00:00

abstract：:Non-compliance has received significant attention in medicine, yet few studies have examined its correlates in autologous hematopoietic SCT (AHSCT) patients. This study examined predictors of non-compliance in a sample of 151 AHSCT patients treated in an outpatient setting. Before AHSCT, participants completed a valid...

journal_title：Bone marrow transplantation

authors： Mumby PB,Hurley C,Samsi M,Thilges S,Parthasarathy M,Stiff PJ

更新日期：2012-04-01 00:00:00

abstract：:Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) and high risk of relapse. However, the stratification systems vary among study groups. Inadequate response at the ...

journal_title：Bone marrow transplantation

authors： Giebel S,Marks DI,Boissel N,Baron F,Chiaretti S,Ciceri F,Cornelissen JJ,Doubek M,Esteve J,Fielding A,Foa R,Gorin NC,Gökbuget N,Hallböök H,Hoelzer D,Paravichnikova E,Ribera JM,Savani B,Rijneveld AW,Schmid C,Wartiov

更新日期：2019-06-01 00:00:00

abstract：:Autologous hematopoietic stem cell transplantation (ASCT) is curative for a proportion of patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). However, there is a small group of patients with high-risk of relapse after ASCT that might benefit from other approaches. We conducted a retrospective analysis on 12...

journal_title：Bone marrow transplantation

authors： Bento L,Boumendil A,Finel H,Khvedelidze I,Blaise D,Fegueux N,Castagna L,Forcade E,Chevallier P,Mordini N,Brice P,Deconinck E,Gramatzki M,Corradini P,Hunault M,Musso M,Tsoulkani A,Caballero D,Nati S,Montoto S,Sured

更新日期：2020-10-12 00:00:00

abstract：:Transplantation of growth factor-mobilized peripheral blood progenitor cells (PBPC) is widely used in the treatment of several neoplastic diseases. While in PBPC harvests the presence of several accessory immune and tumor cells has been documented, that of stromal cells has not been reported. In the present study, we ...

journal_title：Bone marrow transplantation

authors： Fernández M,Simon V,Herrera G,Cao C,Del Favero H,Minguell JJ

更新日期：1997-08-01 00:00:00

abstract：:We retrospectively studied a series of 23 patients (median age 50 years, range 29-59 years) with multiple myeloma (MM), treated in first relapse by a sequential autologous-allogeneic tandem approach. Tandem transplantation (TT) consisted in high dose melphalan (HDT) and auto-SCT followed by an (allo-SCT) preceded by t...

journal_title：Bone marrow transplantation

authors： Karlin L,Arnulf B,Chevret S,Ades L,Robin M,De Latour RP,Malphettes M,Kabbara N,Asli B,Rocha V,Fermand JP,Socie G

更新日期：2011-02-01 00:00:00

abstract：:Relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (ABMT) for malignant lymphoma (ML). Allogeneic transplantation (alloSCT) is a therapeutic option. However, it is associated with a high incidence of transplant-related organ toxicity and mortality. We recently repo...

journal_title：Bone marrow transplantation

authors： Nagler A,Slavin S,Varadi G,Naparstek E,Samuel S,Or R

更新日期：2000-05-01 00:00:00

abstract：:We have used a standardized 21-day expansion protocol to produce cytokine-induced killer (CIK) cells starting from very small amounts of nucleated cells (approximately 15 x 10(6) cells) isolated from cord blood. Mononuclear cells are stimulated with anti CD3 (OKT3) and IFNgamma and then expanded with IL-2. Moreover, w...

journal_title：Bone marrow transplantation

authors： Introna M,Franceschetti M,Ciocca A,Borleri G,Conti E,Golay J,Rambaldi A

更新日期：2006-11-01 00:00:00

abstract：:Although intensive therapy with autologous bone marrow transplantation (ABMT) has improved the outcome of advanced neuroblastoma, nearly half the patients with this disease still relapse after a single ABMT. In our previous study, 10 of 22 patients relapsed within 16 months post-transplantation. Predictive risk-factor...

journal_title：Bone marrow transplantation

authors： Kawa-Ha K,Yumura-Yagi K,Inoue M,Park DY,Okamura T,Yasui M,Oota H,Sakata N,Yoneda M,Imura K

更新日期：1996-06-01 00:00:00

abstract：:Transplantation-associated thrombotic microangiopathy (TA-TMA) is a feared complication of allogeneic hematopoietic SCT (HSCT) owing to its high mortality rate. The use of calcineurin inhibitors or sirolimus (SIR) for GVHD prophylaxis has been suggested as a potential risk factor. However, the impact of tacrolimus (TA...

journal_title：Bone marrow transplantation

authors： Labrador J,López-Corral L,López-Godino O,Vázquez L,Cabrero-Calvo M,Pérez-López R,Díez-Campelo M,Sánchez-Guijo F,Pérez-López E,Guerrero C,Alberca I,Del Cañizo MC,Pérez-Simón JA,González-Porras JR,Caballero D

更新日期：2014-05-01 00:00:00

abstract：:As low trough levels of mycophenolic acid (MPA) have been measured in recipients of allo-SCTs, we performed a pilot study targeting mycophenolate mofetil (MMF) doses according to the MPA area under the concentration (AUC) levels. Twenty-nine patients were transplanted from matched sibling (n=7) and unrelated donors (n...

journal_title：Bone marrow transplantation

authors： Haentzschel I,Freiberg-Richter J,Platzbecker U,Kiani A,Schetelig J,Illmer T,Ehninger G,Schleyer E,Bornhäuser M

更新日期：2008-07-01 00:00:00

abstract：:The efficacy and safety of oral valganciclovir was compared to ganciclovir i.v. in pre-emptive treatment of cytomegalovirus (CMV) in T-cell-depleted allogeneic stem cell transplant (allo-SCT) recipients. A therapeutic guideline was developed to allow the safe application of valganciclovir in allo-SCT recipients requir...

journal_title：Bone marrow transplantation

authors： van der Heiden PL,Kalpoe JS,Barge RM,Willemze R,Kroes AC,Schippers EF

更新日期：2006-04-01 00:00:00

abstract：:Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for primary myelofibrosis (MF) as well as myelofibrosis secondary to other myeloproliferative neoplasms (MPN). Pulmonary hypertension (PH) is a known complication of MF and may occur in up to 50% of such patients. PH (defined as a mea...

journal_title：Bone marrow transplantation

authors： Gupta R,Jamal F,Yang D,Chendri C,Aldoss I,Malki MA,Mei M,Salhotra A,Dobrin S,Tran M,Venkataraman K,Palmer J,Stein AS,Sandhu K,Khaled S,Aribi A,Marcucci G,Forman SJ,Snyder D,Nakamura R,Ali H,Pullarkat V

更新日期：2020-05-01 00:00:00

abstract：:This study was designed to test the efficacy and toxicity of combining high-dose cytarabine (3 g/m2 every 12 h x 8 doses day -7 to day -4, total dose 24 g/m2), methyl prednisolone (0.5 mg/kg every 4 h day -7 to day -1), and cyclophosphamide (CY) (60 mg/kg day -3 and day -2) with either total body irradiation (TBI) (90...

journal_title：Bone marrow transplantation

authors： Broun ER,Tricot G,Akard L,Nichols C,Cheerva A,Jansen J

更新日期：1990-05-01 00:00:00

abstract：:IL-7 and IL-4 are known to influence the growth of cells of the lymphoid lineage. In this study, we investigated the effects of in vivo administration of IL-7 or IL-4 in mice subjected to congenic BM transplant. C57BL/6 Ly5.1+ mice were subjected to TBI, followed by transfer of B and T cell-depleted BM from C57BL/6 Ly...

journal_title：Bone marrow transplantation

authors： Mathur A,Vallera DA,Taylor PA,Widmer MB,Yang C,Prabhu A,Blazar BR

更新日期：1995-07-01 00:00:00

abstract：:Thyroid function was prospectively analysed in 111 consecutive patients in relation to autologous bone marrow transplantation (ABMT). Median follow-up time was 12 (range 3-60) months. As part of the conditioning treatment 58 patients had received total body irradiation (TBI) as a single dose of 7.5 Gy (dose rate 0.15 ...

journal_title：Bone marrow transplantation

authors： Carlson K,Lönnerholm G,Smedmyr B,Oberg G,Simonsson B

更新日期：1992-08-01 00:00:00

abstract：:In an otherwise eligible patient with relapsed lymphoma, inadequate mobilization of hematopoietic stem cells (HSCs) is a limiting factor to proceeding with an autologous hematopoietic cell transplantation (auto-HCT). Multiple strategies have been used to mobilize an adequate number of HSCs with no obvious front-line s...

journal_title：Bone marrow transplantation

authors： Haverkos BM,Huang Y,Elder P,O'Donnell L,Scholl D,Whittaker B,Vasu S,Penza S,Andritsos LA,Devine SM,Jaglowski SM

更新日期：2017-04-01 00:00:00

abstract：:The effectiveness of an antibody-enzyme immunotoxin (eIT) was investigated on human T cells. This enzyme immunotoxin contained glucose oxidase (GO) and lactoperoxidase (LPO) chemically coupled to the pan-leukocyte-specific mouse monoclonal antibody (MoAb) 097 (097-GO and 097-LPO). Human peripheral blood mononuclear ce...

journal_title：Bone marrow transplantation

authors： Ito HO,Morizet J,Coulombel L,Goavec M,Rousseau V,Bernard A,Stanislawski M

更新日期：1989-09-01 00:00:00

abstract：:The aim of the present trial was to investigate the feasibility of high-dose therapy followed by autologous peripheral blood stem cell transplantation (PBSCT) as a component of front-line treatment in patients with disseminated intermediate- and high-grade non-Hodgkin's lymphoma (NHL) aged 61-65 years. From October 19...

journal_title：Bone marrow transplantation

authors： Moreau P,Milpied N,Voillat L,Colombat P,Mahé B,Rapp MJ,Moreau A,Dupas B,Bulabois CE,Juge-Morineau N,Harousseau JL

更新日期：1998-06-01 00:00:00

abstract：:The incidence of bacteremia following hemopoietic SCT (HSCT) changes over time from the procedure. The first 30 days have the highest incidence, both in autologous and allogeneic HSCT recipients. In the following periods, bacteremia is a frequent complication in allogeneic HSCT, especially from alternative donors. Gra...

journal_title：Bone marrow transplantation

authors： Castagnola E,Faraci M,Moroni C,Bandettini R,Caruso S,Bagnasco F,Caviglia I,Natalizia AR,de Fazio V,Morreale G,Lanino E,Dini G,Haupt R

更新日期：2008-06-01 00:00:00

abstract：:The purpose of this study was to evaluate pre-transplant T-cell status in autologous hematopoietic progenitor-cell transplantation (HPCT) recipients. Between 1999 and 2002 we prospectively enrolled 85 autologous HPCT recipients with solid tumors (N = 50) or hematological malignancies (n = 35). Patient diagnoses includ...

journal_title：Bone marrow transplantation

authors： Rosinski SL,McNiece IK,Shpall EJ,Clough N,Russell P,Blunk B,Nieto Y

更新日期：2005-09-01 00:00:00

abstract：:Thrombotic microangiopathy (TMA) is a significant complication after hematopoietic stem-cell transplantation (HSCT); however, there is little information on it following reduced-intensity cord blood transplantation (RI-CBT). We reviewed the medical records of 123 adult patients who received RI-CBT at Toranomon Hospita...

journal_title：Bone marrow transplantation

authors： Narimatsu H,Kami M,Hara S,Matsumura T,Miyakoshi S,Kusumi E,Kakugawa Y,Kishi Y,Murashige N,Yuji K,Masuoka K,Yoneyama A,Wake A,Morinaga S,Kanda Y,Taniguchi S

更新日期：2005-09-01 00:00:00

abstract：:The number of individuals undergoing unrelated cord blood transplantation (UCBT) has increased in recent years; however, information on prognostic factors is limited. We retrospectively analyzed data from 475 children and adolescents receiving UCBT with myeloablative conditioning for acute lymphoblastic leukemia (ALL)...

journal_title：Bone marrow transplantation

authors： Kawahara Y,Morimoto A,Inagaki J,Koh K,Noguchi M,Goto H,Yoshida N,Cho Y,Hori T,Hiwatari M,Kato K,Ogawa A,Hashii Y,Inoue M,Kato K,Atsuta Y,Kimura F,Kato M

更新日期：2020-08-11 00:00:00

abstract：:Forty-six children with juvenile myelomonocytic leukemia (JMML) diagnosed between 1978 and 1993 in 12 centers were retrospectively studied. There is no evidence that any conventional treatment influences the long-term evolution of JMML. Among 28 patients treated without bone marrow transplantation (BMT), 26 died (medi...

journal_title：Bone marrow transplantation

authors： Lutz P,Zix-Kieffer I,Souillet G,Bertrand Y,Dhooge C,Rubie C,Mazingue F,Marguerite F,Machinaud-Lacroix F,Rialland X,Plouvier E,Behar C,Vilmer E,Philippe N,Otten J

更新日期：1996-12-01 00:00:00

abstract：:Seventy consecutive patients with refractory or relapsed Hodgkin's disease who received high-dose chemotherapy followed by autologous stem cell rescue were analyzed to identify clinically relevant predictors of long-term event-free survival. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytara...

journal_title：Bone marrow transplantation

authors： Lancet JE,Rapoport AP,Brasacchio R,Eberly S,Raubertas RF,Linder T,Muhs A,Duerst RE,Abboud CN,Packman CH,DiPersio JF,Constine LS,Rowe JM,Liesveld JL

更新日期：1998-08-01 00:00:00

abstract：SUMMARY:Hematopoietic chimerism (HpC) was assayed monthly using a sensitive, polymerase chain reaction (PCR) -based method in consecutive patients. Between January 1998 and April 2002, 181 patients underwent non-T cell depleted allogeneic hematopoietic cell transplantation (HCT). A total of 163 patients were evaluable ...

journal_title：Bone marrow transplantation

authors： Lee KH,Lee JH,Choi SJ,Lee JH,Kim S,Seol M,Lee YS,Kim WK,Kwon MR,Choi SJ,Park CJ,Chi HS,Lee JS

更新日期：2003-08-01 00:00:00

abstract：:Fetus-to-fetus transplantation has been suggested for the treatment of hemoglobinopathies in utero. However, dissimilar results have to date been obtained by different groups. We describe a case in which fetus-to-fetus transplantation in HLA-identical twins was performed at the 19th week of gestation by infusion of 0....

journal_title：Bone marrow transplantation

authors： Orlandi F,Giambona A,Messana F,Marino M,Abate I,Calzolari R,Damiani F,Jakil C,Renda M,Dieli F,Buscemi F,Westgren M,Ringden O,Maggio A

更新日期：1996-09-01 00:00:00